Update on Stem Cell Trials in ALS: NurOwn and Other Studies
Speakers: Merit Cudkowicz, M.D., MSc, Massachusetts General Hospital and Robert H. Brown, Jr. D.Phil., M.D., University of Massachusetts
Dr. Merit Cudkowicz opens the webinar with an overview of the various stem cell approaches currently being tested as potential treatments for ALS. Drs. Cudkowicz and Brown then discuss NurOwn, a Phase 3 stem cell trial for people with ALS. NurOwn is evaluating the safety and efficacy of repeated administration of NurOwn therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patient's own bone marrow, propagated ex vivo and induced to secrete Neurotrophic factors (NTFs).